Mental health status of transmasculine adults before and after receiving gender affirming hormonal therapy in Gender Health Clinic, King Chulalongkorn Memorial Hospital, Thai Red Cross Society
Recruiting
- Conditions
- Adult transgender menTransgender menTransmasculineMental healthDepression
- Registration Number
- TCTR20240410003
- Lead Sponsor
- Ratchadapisek somphot fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 59
Inclusion Criteria
transmasculine seeking for gender affirming hormone therapy
- age > 20 year
Exclusion Criteria
- Non binary
- Psychiatric disorder
- Receiving hormone or treatment beforehand
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in depression before and after receiving Gender affirming treatment 0,3,6 months questionnaire
- Secondary Outcome Measures
Name Time Method Changes in anxiety before and after receiving Gender affirming treatment 0,3,6 months questionnaire ,Changes in quality of life before and after receiving Gender affirming treatment 0,3,6 months Questionnaire ,Changes in self esteem before and after receiving Gender affirming treatment 0,3,6 months Questionnaire
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link testosterone therapy to depression alleviation in transmasculine adults post-GAHT?
How does GAHT compare to non-hormonal interventions for improving mental health in transmasculine individuals?
What biomarkers correlate with mental health outcomes in TCTR20240410003's transmasculine adult cohort?
What are the long-term adverse events of testosterone therapy in transmasculine adults and their management strategies?
Are there combination therapies with testosterone and SSRIs that enhance mental health outcomes in transmasculine individuals?